Cetera Trust Company N.A Takes Position in Pfizer Inc. (NYSE:PFE)

Cetera Trust Company N.A purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 1,855 shares of the biopharmaceutical company’s stock, valued at approximately $53,000.

Several other institutional investors have also made changes to their positions in PFE. Briaud Financial Planning Inc acquired a new stake in Pfizer in the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the 3rd quarter worth approximately $34,000. VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC lifted its holdings in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer in the 4th quarter worth approximately $36,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on PFE. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $36.33.

Pfizer Stock Performance

PFE opened at $26.26 on Tuesday. Pfizer Inc. has a 12-month low of $25.23 and a 12-month high of $40.37. The stock has a market cap of $148.70 billion, a price-to-earnings ratio of 72.94, a PEG ratio of 1.17 and a beta of 0.61. The business has a 50 day moving average of $27.08 and a 200-day moving average of $28.56. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the firm posted $1.14 earnings per share. The business’s revenue was down 41.3% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.